Jazz Pharmaceuticals
JAZZ
446 hedge funds and large institutions have $7.76B invested in Jazz Pharmaceuticals in 2019 Q4 according to their latest regulatory filings, with 88 funds opening new positions, 164 increasing their positions, 132 reducing their positions, and 34 closing their positions.
159% more first-time investments, than exits
New positions opened: 88 | Existing positions closed: 34
67% more funds holding in top 10
Funds holding in top 10: 3 → 5 (+2)
24% more repeat investments, than reductions
Existing positions increased: 164 | Existing positions reduced: 132
18% more capital invested
Capital invested by funds: $6.55B → $7.76B (+$1.21B)
10% more funds holding
Funds holding: 406 → 446 (+40)
1.61% more ownership
Funds ownership: 90.35% → 91.97% (+1.6%)
15% less call options, than puts
Call options by funds: $33.9M | Put options by funds: $40M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$95.1M |
| 2 |
AQR Capital Management
Greenwich,
Connecticut
|
+$86.1M |
| 3 |
Renaissance Technologies
New York
|
+$58.7M |
| 4 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
+$40.9M |
| 5 |
Marshall Wace
London,
United Kingdom
|
+$34.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity International
Hamilton,
Bermuda
|
-$69.7M |
| 2 |
Franklin Resources
San Mateo,
California
|
-$67.5M |
| 3 |
PI
Putnam Investments
Boston,
Massachusetts
|
-$61.4M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$59.6M |
| 5 |
JP Morgan Chase
New York
|
-$34.7M |
JAZZ Hedge Fund Activity: Q4 2019 in Review
446 of the 5,092 institutional investors tracked by Wall St. Rank reported a position in Jazz Pharmaceuticals (JAZZ) for Q4 2019, worth a combined $7.76B — up 18% from $6.55B a quarter earlier.
Buyers outnumbered sellers: 88 funds opened new JAZZ positions and 34 closed out — a net gain of 54 holders — while 164 added to existing stakes and 132 trimmed.
The largest buyer was Bank of Montreal, adding an estimated $95.1M. The largest seller was Fidelity International, cutting an estimated $69.7M.
- 446 institutional investors held Jazz Pharmaceuticals (JAZZ) as of Q4 2019, up from 406 in Q3 2019.
- Funds reported $7.76B of Jazz Pharmaceuticals stock for Q4 2019, up 18% quarter-over-quarter.
- 88 funds opened new Jazz Pharmaceuticals positions in Q4 2019 and 34 closed out, a net change of +54 holders.
- The largest Jazz Pharmaceuticals buyer in Q4 2019 was Bank of Montreal, an estimated $95.1M added.
- The largest Jazz Pharmaceuticals seller in Q4 2019 was Fidelity International, an estimated $69.7M sold.
Based on aggregated 13F filings for Q4 2019.